Core Viewpoint - International Medical (000516.SZ) emphasizes the importance of traditional Chinese medicine and the concept of "food as medicine," actively exploring innovative health products and services in its hospitals [1] Group 1: Product Development - The hospital's nutrition department has not yet launched homemade yogurt products but is focusing on developing traditional Chinese health products [1] - Products developed include weight loss tea, spleen health tea, liver health tea, constipation tea, throat-soothing tea bags, and blood health tea, which have become popular choices for patient daily health management [1] Group 2: Service Offering - The nutrition department collaborates with the hospital's restaurant to offer a service that combines traditional dietary therapy with modern nutrition, including stews, snacks, noodles, and soybean milk [1] - This service features customized recipes, standardized production, and dedicated delivery, providing dietary options with health benefits for inpatients and those in need [1]

Core Viewpoint - The company is leveraging its resource platform to connect with overseas partners and enhance its international hospital services, aiming to provide high-quality healthcare services to both domestic and international patients, particularly those in sub-health conditions [1] Group 1 - The company has been actively engaging with overseas partners to maximize its resources [1] - The company is focusing on providing quality healthcare services to both domestic and international patients [1] - The proportion of foreign patients in the company's medical institutions is currently small but is showing a year-on-year increase [1]

Core Viewpoint - The company is leveraging its resource platform to connect with overseas partners and enhance its international hospital services, aiming to provide high-quality healthcare services to both domestic and international patients, particularly those in sub-health conditions [1] Group 1 - The company has been actively engaging with overseas partners to maximize its resources [1] - The company is focusing on providing quality healthcare services to both domestic and international patients [1] - The proportion of foreign patients in the company's medical institutions is currently small but is showing a year-on-year increasing trend [1]

Core Viewpoint - International Medical (000516.SZ) has clarified that its medical institutions do not currently engage in organ transplantation or gene therapy [1] Company Summary - The company operates medical institutions that are not involved in organ transplantation [1] - The company also does not participate in gene therapy activities [1] Industry Summary - The statement reflects the company's positioning within the healthcare industry, specifically in relation to advanced medical procedures such as organ transplantation and gene therapy [1]

国际医学在互动平台表示，公司旗下医疗机构暂不涉及器官移植和基因治疗。 （文章来源：第一财经） ...

(一)主营业务影响:1.医疗服务业务板块亏损因素：公司旗下医院尚处于发展初期，虽然营业收入较上年 同期增长约60%，但营业收入中药品、耗材收入占比较大，药品、耗材无利润，导致医院毛利较低，加 之仍处于市场、口碑培育期，人力成本、折旧等固定成本摊销较高等因素，致医院仍处于亏损阶段。2. 煤炭业务板块亏损因素：(1)安佳矿业2025 年受生产系统设备改造、瓦斯治理工程施工、区域性安全管 理等因素影响有效开采时间，致原煤产量偏低，综合成本偏高。(2)煤炭销售单价下降。(3)根据《企业 会计准则》及公司会计政策的相关规定，基于会计谨慎性原则，审慎反映资产质量，对存在减值迹象的 长期资产进行减值测试，预计计提减值准备。3.化工业务板块：因2025年停产大修致产量减少，收入减 少，大修费用增加，导致桐梓化工净利润同比上期减少。(二)非经营性损益的影响:本报告期非经营性损 益影响主要是取得的政府补助及其他营业外收支净收益348.79万元。 本期业绩预亏的主要原因: 格隆汇1月29日丨赤天化(600227.SH)公布，预计2025 年年度实现归属于母公司所有者的净利润为-2.88 亿元到-3.8亿元，与上年同期(法定披露数据 ...

赤天化公告称，预计2025年年度归属于母公司所有者的净利润为 -2.88亿元到 -3.80亿元，将连续亏损。 上年同期净利润为 -8669.35万元。扣非后净利润为 -2.95亿元到 -3.87亿元。医疗服务业务虽营收增约 60%，但药品、耗材无利润且成本高致亏损；煤炭业务因产量低、单价降及计提减值准备亏损；化工业 务因停产大修收入减少、费用增加，净利润同比减少。非经营性损益有净收益348.79万元。 ...

南财智讯1月29日电，赤天化发布业绩预亏公告，预计2025年年度实现归属于母公司所有者的净利润 为-28,800万元到-38,000万元，与上年同期（法定披露数据）相比，将出现连续亏损。业绩预亏的主要 原因：（一）主营业务影响：1.医疗服务业务板块亏损因素：公司旗下医院尚处于发展初期，虽然营业 收入较上年同期增长约60%，但营业收入中药品、耗材收入占比较大，药品、耗材无利润，导致医院毛 利较低，加之仍处于市场、口碑培育期，人力成本、折旧等固定成本摊销较高等因素，致医院仍处于亏 损阶段；2.煤炭业务板块亏损因素：（1）安佳矿业2025年受生产系统设备改造、瓦斯治理工程施工、 区域性安全管理等因素影响有效开采时间，致原煤产量偏低，综合成本偏高；（2）煤炭销售单价下 降；（3）根据《企业会计准则》及公司会计政策的相关规定，基于会计谨慎性原则，审慎反映资产质 量，对存在减值迹象的长期资产进行减值测试，预计计提减值准备；3.化工业务板块：因2025年停产大 修致产量减少，收入减少，大修费用增加，导致桐梓化工净利润同比上期减少。（二）非经营性损益的 影响：本报告期非经营性损益影响主要是取得的政府补助及其他营业外收支净收益 ...

Core Viewpoint - China Galaxy Securities is optimistic about the pharmaceutical industry's investment opportunities in 2026, focusing on hard technology in medicine, innovation, and overseas expansion, while seeking alpha in niche segments [1] Group 1: Investment Trends - In Q4 2025, public fund holdings in pharmaceuticals decreased, indicating an overall low allocation level [1] - The market value of pharmaceutical theme funds decreased by 9.73% to 205.9 billion yuan, which is 66.54% higher than the average since 2019 [1] - The market value of the pharmaceutical biotechnology sector fell by 18.81% to 312.5 billion yuan, with a holding ratio of 8.12%, below the historical average by 3.89 percentage points [1] Group 2: Stock Performance - The top five pharmaceutical stocks held by public funds in Q4 2025 saw significant reductions in both the number of funds and total market value, with notable declines in stocks like Heng Rui Medicine and WuXi AppTec [2] - The concentration of holdings has shifted from innovative drugs to medical devices and services, indicating a change in market investment focus [2] Group 3: Industry Data Overview - The pharmaceutical manufacturing industry's revenue has shown a slight decline, with a year-on-year decrease of 1.2% in Q4 2025 [3] - Medical service volumes remained stable, with a total of 1.86 billion outpatient visits in early 2025, reflecting a 0.1% year-on-year decrease [3] - The overall operation of the medical insurance fund has been stable, with total income of 2.632 trillion yuan and total expenditure of 2.110 trillion yuan from January to November 2025 [3] Group 4: Market Comparison - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a rolling P/E ratio of 38.19 compared to 14.14 for the CSI 300, indicating a premium of 170.14% over the index [3] - The SW pharmaceutical biotechnology index increased by 1.44% from early 2024 to January 28, 2026, while the CSI 300 rose by 37.15%, showing a relative underperformance of 35.71% for the pharmaceutical sector [3]

Investment Rating - The investment rating for the company is "Buy" (首次) [1] Core Insights - The company is a leading small molecule CDMO with over 25 years of experience, currently transitioning from a single small molecule business to a dual-driven model of "small molecule + emerging business" [5][17] - The new business segment is experiencing rapid growth, contributing significantly to revenue, while traditional business remains resilient [5][6] - The company is expected to achieve net profits of 1.16 billion, 1.30 billion, and 1.51 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 3.23, 3.59, and 4.18 yuan [5] Financial Summary and Valuation Metrics - Revenue projections for 2025, 2026, and 2027 are 6.66 billion, 7.69 billion, and 8.94 billion yuan respectively, with year-over-year growth rates of 14.7%, 15.4%, and 16.3% [8] - The company’s gross margin is projected to be around 42% for 2025, with a net margin of 17.5% [8] - The current P/E ratios are 31.0, 27.8, and 23.9 for 2025, 2026, and 2027 respectively [8] Business Development and Strategy - The company is focusing on expanding its capabilities in the peptide and small nucleic acid sectors, with significant investments in production capacity [6][79] - As of H1 2025, the new business segment generated 756 million yuan in revenue, a 51.22% increase year-over-year, accounting for 23.71% of total revenue [6] - The company has established partnerships with major pharmaceutical companies, enhancing its market presence and customer base [44] Industry Trends - The global healthcare investment environment is gradually recovering, with a total investment of 63.88 billion USD in 2025, marking a 10.13% increase year-over-year [47] - The domestic healthcare investment market is also improving, with a total of 73.78 billion yuan in 2025, a 39.05% increase year-over-year [53] - The global CDMO market is expected to grow significantly, with the small molecule CDMO/CMO market projected to reach 112 billion USD by 2029, growing at a CAGR of 16.6% [65]